Prospects for Chemoprevention in Cohorts with Cancer Risk Markers

Guest Editors

Gary J. Kelloff, MD, and Charles W. Boone, MD, PhD

Chemoprevention Branch
National Cancer Institute
National Institutes of Health
Bethesda, Maryland
Foreword: Prospects for Chemoprevention in Cohorts with Cancer Risk Markers

Editor's Note

ARTICLES

OVERVIEW OF CANCER RISK MARKERS AND CHEMOPREVENTION

Risk Biomarkers and Current Strategies for Cancer Chemoprevention

Genetic Susceptibility to Cancer From Exogenous and Endogenous Exposures
Heather Spencer-Feigelson, Ronald K. Ross, Mimi C. Yu, Gerhard A. Coetzee, Juergen K.V. Reichardt, and Brian E. Henderson

Relevance of Cyclin D1 and Other Molecular Markers to Cancer Chemoprevention
I. Bernard Weinstein

Cancer Risk Factors for Selecting Cohorts for Large-Scale Chemoprevention Trials
Peter Greenwald

STATE OF THE ART METHODOLOGY FOR DETECTING SUBJECTS AT HIGH RISK:
METHODS FOR MEASURING GENE-SPECIFIC RISK FACTORS AND GENERAL
GENETIC DAMAGE AND APPLICABILITY TO CHEMOPREVENTION
TECHNOLOGY, SENSITIVITY, ACCURACY, PREVALENCE IN NORMAL
TISSUE OF HIGH-RISK SUBJECTS

Inherited Susceptibility and Acquired Allelic Imbalance in Rat Mammary Carcinogenesis
Michael N. Gould, Ronald A. Lubet, Gary J. Kelloff, and Jill D. Haag

Detection of Genomic Alterations in Human Cervical Cancer by Two-Dimensional Gel Electrophoresis
Jiafan Liu, Yian Wang, Ping Gu, James Patrick, Keith A. Crist, Carol L.K. Sabourin, Gary D. Stoner, Michele F. Mitchell, James D. Fanning, Kitai Kim, Peter J. Goldblatt, Gary J. Kelloff, Charles W. Boone, and Ming You

DNA Quantification in Cervical Intraepithelial Neoplasia Thick Tissue Sections by Confocal Laser Scanning Microscopy
Keith A. Crist, Kitai Kim, Peter J. Goldblatt, Charles W. Boone, Gary J. Kelloff, and Ming You

Detection of Chromosome Instability of Tissue Fields at Risk: In Situ Hybridization
Walter N. Hittelman, Hyo J. Kim, Jin S. Lee, Dong M. Shin, Scott M. Lippman, Jin Kim, Jae Y. Ro, and Waun Ki Hong

(continued on next page)

• FRONT COVER: Cover depicts well-known cancer risk biomarkers, describing cohorts for chemopreventive intervention (e.g., carriers of BRCA and p53 mutations). Chemopreventive intervention could possibly modulate some of these biomarkers (e.g., ras oncogene overexpression in the colon). Graphics were provided by Technical Resources International, Inc. and Mr. Zaldy Dingle of CCS Associates.
Application of Molecular Epidemiology to Lung Cancer Chemoprevention
LaVerne A. Mooney and Frederica P. Perera .......................... 63

BIOSTATISTICIANS’ PERSPECTIVES ON CANCER CHEMOPREVENTION
Defining and Analyzing Cohorts Using Molecular Markers of Cancer Risk
Steven D. Mark .................................................................. 69

RISK MARKERS AND CANCER CHEMOPREVENTION TRIALS—
COHORTS AND ENDPOINTS
Multiple Sites
Mutagen Sensitivity as a Marker of Cancer Susceptibility
Margaret R. Spitz, Xifeng Wu, Hong Jiang, and T.C. Hsu ...................... 80
Carcinogen-DNA and Protein Adducts: Biomarkers for Cohort Selection and Modifiable
Endpoints in Chemoprevention Trials
Thomas W. Kensler and John D. Groopman .................................. 85
Smokers and Urinary Genotoxins: Implications for Selection of Cohorts and Modulation of
Endpoints in Chemoprevention Trials
Silvio De Flora, Anna Camoirano, Maria Bagnasco, Carlo Bennicelli, Nico van Zandwijk,
Gea Wigbout, Geng-sun Qian, Yuang-rong Zhu, and Thomas W. Kensler ........ 92
Mutational Specificity and Cancer Chemoprevention
John Curry, Mohammed Khaidakov, Aparecido da Cruz, Larissa Karnaoukhova,
Wolfgang C. Kusser, Johan de Boer, Joyce Moffat, and Barry W. Glickman ........ 99

Breast
Classification of Duct Carcinoma In Situ (DCIS) With a Characterization of High Grade
Lesions: Defining Cohorts for Chemoprevention Trials
Michael D. Lagios .................................................................. 108
Identification of a Chemoprevention Cohort From a Population of Women at
High Risk for Breast Cancer
Carol J. Fabian, Sahar Kamel, Carola Zalles, and Bruce F. Kimler .............. 112
Ethical and Scientific Considerations for Chemoprevention Research in Cohorts
at Genetic Risk for Breast Cancer
Susan G. Nayfield .................................................................. 123

Colon
Cohorts With Familial Disposition for Colon Cancers in Chemoprevention Trials
Randall W. Burt .................................................................... 131
Inherited and Acquired Risk Factors in Colonic Neoplasia and Modulation by
Chemopreventive Interventions
Martin Lipkin, Kan Yang, Winfried Edelman, Harold Newmark, Kun-Hua Fan, Mauro Risio,
and Raju Kucherlapati ............................................................ 136
Large Bowel Adenomas: Markers of Risk and Endpoints
John A. Baron ....................................................................... 142

Prostate
The Role of Prostate-Specific Antigen in the Chemoprevention of Prostate Cancer
E. David Crawford, Edward P. DeAntoni, and Colleen A. Ross .................. 149
Prostatic Intraepithelial Neoplasia (PIN) and Other Prostatic Lesions as Risk Factors and
Surrogate Endpoints for Cancer Chemoprevention Trials
David G. Bostwick and Joseph W. Aquilina .................................... 156
Lymphoma
Molecular Genetic Biomarkers in Hematological Malignancies
Adam Bagg and Jeffrey Cossman .............................. 165

Lung
K-ras Mutation in Sputum of Patients With or Without Lung Cancer
Ze’ev Ronai, Marina S. Yakubovskaya, Edith Zhang, and Gennady A. Belitsky ..................... 172
Clinical Detection of Lung Cancer Progression Markers
Melvyn S. Tockman .............................................. 177
Examination of p53 Alterations and Cytokeratin Expression in Sputa Collected From
Patients Prior to Histological Diagnosis of Squamous Cell Carcinoma
Marshall Anderson, Sue Sladon, Ruth Michels, Lois Davidson, Kenneth Conwell II,
John Lechner, Wilbur Franklin, Geno Saccomanno, and Jonathan Wiest ....................... 185

Urinary Bladder
Genetic Alterations as Clonal Markers for Bladder Cancer Detection in Urine
Li Mao .............................................................. 191
G-Actin as a Risk Factor and Modulatable Endpoint for Cancer Chemoprevention Trials
George P. Hemstreet III, Jian Yu Rao, Robert E. Hurst, Rebecca B. Bonner, Przemko Waliszewski,
H. Barton Grossman, Monica Liebert, and Barbara L. Bane ................................. 197

Author Index to Supplement 25 .............................................. 205
Subject Index to Supplement 25 ............................................. 206